JP2025130076A5 - - Google Patents

Info

Publication number
JP2025130076A5
JP2025130076A5 JP2025061657A JP2025061657A JP2025130076A5 JP 2025130076 A5 JP2025130076 A5 JP 2025130076A5 JP 2025061657 A JP2025061657 A JP 2025061657A JP 2025061657 A JP2025061657 A JP 2025061657A JP 2025130076 A5 JP2025130076 A5 JP 2025130076A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
chain variable
variable region
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025061657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025130076A (ja
Filing date
Publication date
Priority claimed from JP2022579884A external-priority patent/JP7720871B2/ja
Application filed filed Critical
Publication of JP2025130076A publication Critical patent/JP2025130076A/ja
Publication of JP2025130076A5 publication Critical patent/JP2025130076A5/ja
Pending legal-status Critical Current

Links

JP2025061657A 2020-06-23 2025-04-03 抗cd38抗体及びその使用 Pending JP2025130076A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063042773P 2020-06-23 2020-06-23
US63/042,773 2020-06-23
JP2022579884A JP7720871B2 (ja) 2020-06-23 2021-06-22 抗cd38抗体及びその使用
PCT/CN2021/101408 WO2021259227A1 (zh) 2020-06-23 2021-06-22 抗cd38抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022579884A Division JP7720871B2 (ja) 2020-06-23 2021-06-22 抗cd38抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2025130076A JP2025130076A (ja) 2025-09-05
JP2025130076A5 true JP2025130076A5 (cg-RX-API-DMAC7.html) 2025-10-28

Family

ID=79281978

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022579884A Active JP7720871B2 (ja) 2020-06-23 2021-06-22 抗cd38抗体及びその使用
JP2025061657A Pending JP2025130076A (ja) 2020-06-23 2025-04-03 抗cd38抗体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022579884A Active JP7720871B2 (ja) 2020-06-23 2021-06-22 抗cd38抗体及びその使用

Country Status (6)

Country Link
US (1) US12497463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4169949A4 (cg-RX-API-DMAC7.html)
JP (2) JP7720871B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027270A (cg-RX-API-DMAC7.html)
CN (1) CN116670285A (cg-RX-API-DMAC7.html)
WO (1) WO2021259227A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021259227A1 (zh) * 2020-06-23 2021-12-30 江苏康缘药业股份有限公司 抗cd38抗体及其用途
AU2025213136A1 (en) 2024-01-24 2026-07-16 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459007A (en) 1891-09-08 Porte
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1174440A1 (en) * 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
SG10201913447SA (en) * 2013-10-31 2020-02-27 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
MX373301B (es) * 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
AU2015242752A1 (en) 2014-04-04 2016-10-20 Kyowa Hakko Kirin Co., Ltd. Anti-death receptor 3 (DR3) antagonistic antibodies with reduced agonistic activity
PE20171094A1 (es) * 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody
WO2021259227A1 (zh) * 2020-06-23 2021-12-30 江苏康缘药业股份有限公司 抗cd38抗体及其用途

Similar Documents

Publication Publication Date Title
JP2021191763A5 (cg-RX-API-DMAC7.html)
JP2022031635A5 (cg-RX-API-DMAC7.html)
CN105968206B (zh) 抗erbb3抗体
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP2023134618A5 (cg-RX-API-DMAC7.html)
JP2019536470A5 (cg-RX-API-DMAC7.html)
JP2021514973A5 (cg-RX-API-DMAC7.html)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
RU2007139953A (ru) Антитела к ccr5 и их применение
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2009532336A5 (cg-RX-API-DMAC7.html)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2024520188A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2016503067A5 (cg-RX-API-DMAC7.html)
JP2022549172A5 (cg-RX-API-DMAC7.html)
US10836833B2 (en) Cell engaging binding molecules
JP2021511387A5 (cg-RX-API-DMAC7.html)
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2023509373A5 (cg-RX-API-DMAC7.html)
JP2022517216A5 (cg-RX-API-DMAC7.html)
JP2021518748A5 (cg-RX-API-DMAC7.html)
JP2018529672A5 (cg-RX-API-DMAC7.html)
JP2024517953A5 (cg-RX-API-DMAC7.html)
JP2024523885A5 (cg-RX-API-DMAC7.html)